We serve Chemical Name:Methylbenzene-13C6 CAS:287399-35-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Methylbenzene-13C6
CAS.NO:287399-35-3
Synonyms:Methylbenzene-13C6
Molecular Formula:C7H8
Molecular Weight:98.09430
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:98.08270
LogP:1.99500
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN1294 – class 3 – PG 2 – Tolu
Packing Group:
Contact us for information like Methylbenzene-13C6 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methylbenzene-13C6 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methylbenzene-13C6 Use and application,Methylbenzene-13C6 technical grade,usp/ep/jp grade.
Related News: The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma��s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution. Methylbenzene-13C6 manufacturer The Breakthrough Designation for the iLet Bionic Pancreas System contemplates configurations with most insulin analogs approved for pumping as well as dasiglucagon, Zealand Pharma��s stable pumpable glucagon analog, which has a unique stability profile in a ready-to-use aqueous solution. Methylbenzene-13C6 supplier During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. Methylbenzene-13C6 vendor At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. Methylbenzene-13C6 factory During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology.
